In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Svlsf V, Llc. has picked up 2,857,667 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,857,667 representing a 15.3% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)’s key stats reveals a current market capitalization of 23.71 million based on 18.65 million shares outstanding and a price at last close of $1.23 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-30, George picked up 12,422 at a purchase price of $12.00. This brings their total holding to 90,764 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.